Completed NA INTERVENTIONAL 4-arm NCT05527106

Evaluation of the Effect of Citicoline and Docosahexaenoic Acid (DHA) on the Visual Function of Patients With Glaucoma

Evaluation of the Effect of Citicoline (Cebrolux 800 mg) and Docosahexaenoic Acid (DHA) Compound (BrudyPio 1.5 g) on the Visual Function of Patients With Glaucoma With a Pilot Study

Sponsor: Institut Catala de Retina

Conditions Glaucoma

Interventions Citicoline Citicoline and Docosahexaenoic Acid (DHA) Docosahexaenoic Acid (DHA) Vitamin C

Updated 3 times since 2022 Last updated: Sep 1, 2022 Started: Mar 12, 2015 Primary completion: May 25, 2022 Completion: May 25, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05527106, this NA trial focuses on Glaucoma and remains completed. Sponsored by Institut Catala de Retina, it has been updated 3 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Sep 2022 — Jul 2024 [monthly]

Completed NA

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Catala de Retina

Data source: Institut Catala de Retina

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain